---
document_datetime: 2023-09-21 17:27:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_en.pdf
document_name: zyclara-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8707849
conversion_datetime: 2025-12-26 11:49:18.020151
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength    | Pharmaceutical form   | Route of administration   | Immediate packaging    | Content (concentration)   | Pack size   |
|------------------|-------------------|-------------|-----------------------|---------------------------|------------------------|---------------------------|-------------|
| EU/1/12/783/001  | Zyclara           | 3.75% (w/w) | Cream                 | Cutaneous use             | sachet (polyester/Alu) | 250 mg                    | 14 sachets  |
| EU/1/12/783/002  | Zyclara           | 3.75% (w/w) | Cream                 | Cutaneous use             | sachet (polyester/Alu) | 250 mg                    | 28 sachets  |
| EU/1/12/783/003  | Zyclara           | 3.75% (w/w) | Cream                 | Cutaneous use             | sachet (polyester/Alu) | 250 mg                    | 56 sachets  |